Cancer Genetics Partners With Roche Unit

Cancer Genetics, an oncology diagnostics company, said Monday it has partnered with Ventana Medical Systems, a member of Switzerland’s Roche Group, to provide access to a newly-approved predictive biomarker test for new immuno-oncology therapy for advanced bladder cancer. Cancer Genetics said will work to enable rapid patient access to the test following the U.S. Food and Drug Administration’s approval of Roche’s VENTANA PD-L1.

CGI participated in a new program launched by Ventana that provides pre-launch pathologist training and supports the lab in validating the test. The agreement ensures that CGI is one of the first laboratories in the United States with pathologists trained to use and interpret the test.

Leave a Comment